Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Vesigel by UroGen Pharma for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer): Likelihood of Approval
Vesigel is under clinical development by UroGen Pharma and currently in Pre-Registration for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial...
Imiquimod + zalifrelimab by UroGen Pharma for Prostate Cancer: Likelihood of Approval
Imiquimod + zalifrelimab is under clinical development by UroGen Pharma and currently in Phase I for Prostate Cancer. According to...
Imiquimod + zalifrelimab by UroGen Pharma for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer): Likelihood of Approval
Imiquimod + zalifrelimab is under clinical development by UroGen Pharma and currently in Phase I for Non Muscle Invasive Bladder...
Vesigel by UroGen Pharma for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer): Likelihood of Approval
Vesigel is under clinical development by UroGen Pharma and currently in Phase III for Non Muscle Invasive Bladder Cancer (NMIBC)...
Risk adjusted net present value: What is the current valuation of UroGen Pharma's Vesigel?
Vesigel is a small molecule commercialized by UroGen Pharma, with a leading Phase III program in Non Muscle Invasive Bladder...